Efficacy Sustained After Dose De-escalation of Certolizumab Pegol in Rheumatoid Arthritis Patients: Post-hoc Analysis of the RAPID 2 Open-label Extension
Author(s):
Smolen, J.; Vollenhoven, R. van; Kavanaugh, A.; Luijtens, K.; Heijde, D. van der; Curtis, J.
